By Akshat Jain MD, MPH Hematology Oncology and Cellular Therapy Faculty Department of Pediatrics & Clinical Medicine Loma Linda University…
Hematologists & Oncologists from Across Country Met to Discuss Latest Updates in Care On August 4-5, 2023, the Binaytara…
X-7/7 trial: Alternative fixed dosing of capecitabine associated with similar efficacy with better safety profile By Drs. Arya Mariam…
By Dr. Aakash Desai Mayo Clinic KEYNOTE-789: No Significant Efficacy Benefit with Addition of Pembrolizumab to Chemotherapy in TKI-Resistant,…
By Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center Hodgkin’s lymphoma (HL) has had an exciting and…
Imetelstat in low-risk MDS for transfusion independence By Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center …
By Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center Low-risk MDS had many exciting updates, starting with…
Author: Lei Deng, MD Roswell Park Comprehensive Cancer Center Live report from ASCO23, Chicago, IL June 6, 2023 …
Author: Lei Deng, MD Roswell Park Comprehensive Cancer Center Live report from ASCO23, Chicago, IL June 6, 2023 …
Palbociclib after progression on Palbociclib in HR-positive HER2-negative breast cancer does not show improvement in progression-free survival By Dr.…